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Summary 
The Ca2+­binding protein of the EF­hand type, S100B, is an intracellular regulator and an extra­
cellular signal. Within cells S100B interacts with several proteins thereby regulating energy 
metabolism, Ca2+ homeostasis, protein phosphorylation and degradation, and cell locomotion, 
proliferation and differentiation. Once secreted/released, S100B exerts autocrine and paracrine 
effects on responsive cells by engaging the receptor for advanced glycation end products. How­
ever, recent evidence suggests that S100B might also activate basic fi broblast growth factor 
receptor 1 via prior binding to basic fi broblast growth factor.
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Introduction
S100B protein belongs to the S100 family of Ca2+­binding proteins of the EF­
hand type exclusively expressed in vertebrates (Donato et al., 2009). S100B expres­
sion is restricted to a limited number of cell types where it is found diffusely in the 
cytoplasm and associated with intracellular membranes, microtubules and type III 
intermediate fi laments. S100B is a Ca2+ sensor protein: upon binding of Ca2+, S100B 
undergoes a conformational change resulting in the exposure to the solvent of a 
hydrophobic patch through which it interacts with target proteins thereby regulat­
ing their functions. Certain cell types (e.g. astrocytes and adipocytes) secrete S100B 
and all S100B­expressing cells passively release the protein in case of damage and/
or necrosis. Once outside the cell, S100B exerts autocrine and paracrine effects mostly, 
though not exclusively, by engaging the receptor for advanced glycation end prod­
ucts (RAGE) on responsive cells (Donato, 2007). Therefore, S100B functions as an 
intracellular regulator as well as an extracellular signal.
Intracellular S100B
Within cells, S100B regulates enzyme activities, the state of assembly of cytoskel­
eton components, transcription factors, Ca2+ homeostasis, protein phosphorylation 
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and degradation, and cell locomotion, proliferation and differentiation (Donato et al., 
2009). S100B has been long implicated in cell proliferation and differentiation with 
scant information about the underlying molecular mechanisms, though. We have 
investigated this latter issue using three cell systems, i.e. PC12 neuronal cells, astro­
cyte cell lines and myoblast cell lines.
We choose PC12 neuronal cells because they do not express S100B. PC12 cells that 
were forced to express S100B proliferated at a higher rate, compared to controls, and 
were unresponsive to the differentiating activity of nerve growth factor (NGF) (Arcu­
ri et al., 2005). In PC12 cells S100B activated a PI3K/Akt/p21WAF1/cyclin D1/cdk4/
Rb/E2F pathway responsible for enhanced cell proliferation, and reduced apoptosis 
and sensitivity to NGF.
Astrocytes express relatively high amounts of S100B (Donato et al., 2009). Reduc­
ing S100B expression levels in astrocyte cell lines by transient transfection with S100B 
small interfering (si) RNA resulted in a modest decrease in cell proliferation, acqui­
sition of a differentiated phenotype, and decreased migration (Brozzi et al., 2009). 
Contrary to control cells that exhibited stress fibers and little or no GFAP filaments, 
S100B siRNA­transfected astrocytes showed dissolution of stress fibers, collapse of 
F­actin onto the plasma membrane and GFAP filaments. S100B interacted with and 
activated Src kinase that in turn activated PI3K: this latter activated the RhoA/ROCK 
module thus promoting the formation of stress fibers (which are responsible for cell 
locomotion), and Akt thus inhibiting the GSK3b/Rac1 module (which is responsible 
to the formation of cell extensions). Thus, as long as S100B was expressed at relative­
ly high levels astrocytes maintained a migratory capacity and did not differentiate. 
Combined with in vivo data (Raponi et al., 2007), our results suggest that reduction of 
S100B expression levels might be permissive for astrocyte precursor cells to differenti­
ate, and astrocytes resume expressing the protein at completion of the differentiation 
program. The molecular mechanisms regulating the reduction of S100B expression at 
the beginning of astrocyte differentiation and resumption of S100B expression in dif­
ferentiated astrocytes remain to be elucidated.
Myoblast cell lines express moderate amounts of S100B (Donato et al., 2009). 
Overexpression of S100B in myoblasts resulted in reduction of differentiation (i.e., 
absence of expression of the muscle­specific transcription factors, MyoD and myo­
genin, and no myotube formation), whereas reduction of S100B expression levels by 
RNA interference resulted in enhanced differentiation (Tubaro et al., 2010). S100B 
activated the IKKb/NF­κB module thereby inhibiting MyoD and, hence, myogenin 
expression. It is known that NF­κB inhibits MyoD expression in myoblasts (Guttridge 
et al., 2000; Bakkar et al., 2008). S100B is expressed in skeletal muscle satellite cells 
(Tubaro et al., 2010), i.e. the adult stem cells of muscle tissue that play a fundamental 
role in muscle regeneration (Chargé and Rudnicki, 2004); thus the protein might play 
a physiological role in the regulation of differentiation of activated satellite cells fol­
lowing muscle damage.
Extracellular S100B
Astrocytes secrete S100B constitutively, and S100B secretion can be stimulated 
or reduced by a number of factors/conditions (Donato et al., 2009). S100B has been 
long associated with promotion of neuronal survival and neurite extension at low, 
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physiological concentrations, and to cause neuronal death at high (i.e., submicromo­
lar/micromolar) concentrations. All these effects require S100B interaction with and 
stimulation of RAGE (Huttunen et al., 2000). RAGE is a multiligand receptor of the 
immunoglobulin superfamily involved in the innate immune response; however, 
RAGE also plays a role in tissue development (Rauvala and Rouhiainen, 2010). Also, 
low S100B protects neuronal cells against b­amyloid toxicity via RAGE engagement 
(Businaro et al., 2006). However, high S100B concentrations cause excessive RAGE 
stimulation in neuronal cells resulting in overproduction of reactive oxygen species 
(ROS), the ultimate cause of apoptosis (Huttunen et al., 2000).
Extracellular S100B plays a role in neuroinflammation. Indeed, S100B was shown 
to activate microglia, the brain resident macrophages, albeit at high concentrations 
only. In the presence, but not absence of bacterial endotoxin or INF­g, S100B upregu­
lated inducible nitric oxide (NO) synthase and stimulated NO release (Petrova et al., 
2000; Adami et al., 2001, 2004). However, S100B upregulates the expression of the 
pro­inflammatory enzyme, COX­2, in microglia and stimulates the release of IL­1b 
and TNF­a, in the absence of co­factors in a RAGE­dependent manner (Bianchi et 
al., 2007, 2010). Also, at non pro­inflammatory doses, S100B synergizes with non pro­
inflammatory doses of IL­1b and TNF­a to upregulate COX­2 expression (Bianchi et 
al., 2010). Current work suggests that high S100B stimulates microglial chemotaxis 
via RAGE­dependent induction and secretion of certain chemokines (Bianchi R., 
Kastrisianaki E., Giambanco I. and Donato R., submitted for publication). The par­
ticipation of S100B in neuroinflammation is supported by findings by other research 
groups (for review see Donato et al., 2009). In this context, S100B exhibits properties 
of a damage associated molecular pattern (DAMP) factor, signaling tissue damage 
and participating in the inflammatory response. However, S100B is not just a DAMP 
factor as at low concentrations it exerts trophic effects on neurons (Huttunen et al., 
2000) and counteracts the pro­inflammatory activity of the neurotoxin, trimethyltin, 
on astrocytes and microglia (Reali et al., 2005).
Extracellular S100B also plays a role in myogenesis. S100B inhibits myoblast dif­
ferentiation (Sorci et al., 2003) and stimulates the proliferation of myoblasts and 
reduces their apoptosis (Riuzzi et al., 2006). Surprisingly, these effects are independ­
ent of RAGE signaling despite myoblasts do express RAGE (Sorci et al., 2003). Inci­
dentally, during the course of these studies we serendipitously found that RAGE, 
activated by another of its ligands, i.e. HMGB1 (amphoterin), transduces a promy­
ogenic, anti­proliferative and anti­tumor effect (Sorci et al., 2004; Riuzzi et al., 2006, 
2007). Recent work shows that under conditions that favor myoblast differentiation 
and fusion into myotubes S100B causes the formation of an FGFR1/bFGF/S100B/
RAGE transcomplex thereby enhancing FGFR1’s mitogenic and anti­myogenic signal­
ing and reducing RAGE’s promyogenic signaling (Riuzzi F., Sorci G. and Donato R., 
submitted for publication).
Conclusions
S100B is a multifaceted protein in that it exerts intracellular and extracellular reg­
ulatory effects and, once released into the extracellular space, it can affect neuronal, 
microglial and myogenic cells with different outcomes depending on its concentra­
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tion. Although RAGE is the receptor transducing S100B effects in several cell types 
(Donato, 2007), S100B might activate at least another receptor (i.e. FGFR1) via prior 
binding to FGFR1­bound bFGF. Whether or not S100B alters the function of other 
receptors via interaction with their canonical ligands remains to be established.
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